Piramal Pharma Ltd (PPLPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003728, "name": "Piramal Pharma", "stock_name": "Piramal Pharma", "full_name": "Piramal Pharma Ltd", "name_url": "stocks-analysis/piramal-pharma", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "166.10", "chg": 1.4, "chgp": "0.85%", "dir": 1, "prev_price": "164.70", "mcapval": "21,906.00 Cr", "mcap": "Small Cap", "scripcode": 543635, "symbol": "PPLPHARMA", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE0DK501011", "curr_date": "Feb 18", "curr_time": "", "bse_nse_vol": "26.08 lacs", "exc_status": "Active", "traded_date": "Feb 18, 2026", "traded_date_str": "2026 02 18", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/piramal-pharma-1003728-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Piramal Pharma Ltd Technical Momentum Shifts Amid Bearish Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-technical-momentum-shifts-amid-bearish-signals-3843644", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PiramalPharmaLt_technicaldot_3843644.png", "date": "2026-02-17 08:07:08", "description": "Piramal Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest intraday decline, the stock’s technical profile reveals growing downside pressure, underscored by deteriorating moving averages and bearish MACD readings, raising concerns for investors amid a challenging pharmaceutical sector backdrop." }, { "title": "Piramal Pharma Ltd Upgraded to Sell by MarketsMOJO Amid Mixed Financial and Technical Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/piramal-pharma-ltd-upgraded-to-sell-by-marketsmojo-amid-mixed-financial-and-technical-signals-3841918", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PiramalPharmaLt_mojoScore_3841918.png", "date": "2026-02-16 08:41:57", "description": "Piramal Pharma Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite ongoing financial challenges. The revision is driven primarily by a change in technical indicators, while fundamental concerns around profitability and debt servicing persist. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the rating adjustment." }, { "title": "Piramal Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-3841743", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PiramalPharmaLt_technicaldot_3841743.png", "date": "2026-02-16 08:05:21", "description": "Piramal Pharma Ltd has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook, reflecting nuanced changes in key indicators such as MACD, RSI, and moving averages. Despite a modest day gain of 1.56%, the stock’s broader trend remains cautious amid mixed signals from weekly and monthly charts." }, { "title": "Piramal Pharma Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/piramal-pharma-ltd-is-rated-strong-sell-3832529", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PiramalPharmaLt_mojoScore_3832529.png", "date": "2026-02-11 10:11:38", "description": "Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Piramal Pharma Ltd Opens with Strong Gap Up, Reflecting Positive Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-opens-with-strong-gap-up-reflecting-positive-market-sentiment-3818207", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PiramalPharmaLt_gapup_3818207.png", "date": "2026-02-03 10:08:16", "description": "Piramal Pharma Ltd commenced trading on 3 Feb 2026 with a notable gap up, opening 5.8% higher than its previous close, reflecting a strong start and positive sentiment in the Pharmaceuticals & Biotechnology sector. The stock outperformed both its sector and the broader market indices, signalling renewed momentum despite a challenging recent performance." }, { "title": "Piramal Pharma Gains 2.08%: 4 Key Factors Driving the Week’s Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-gains-208-4-key-factors-driving-the-weeks-volatility-3812665", "imagepath": "", "date": "2026-01-31 11:00:11", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 27:</strong> New 52-week low hit at Rs.150.15</p>\n <p><strong>Jan 28:</strong> Sharp surge in open interest signalling bearish market positioning</p>\n <p><strong>Jan 29:</strong> Further 52-week low recorded at Rs.148.3 amid volatile trading</p>\n <p><strong>Jan 30:</strong> Week closes at Rs.154.55, up 2.08% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.151.40</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs..." }, { "title": "Piramal Pharma Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/piramal-pharma-ltd-is-rated-strong-sell-3812395", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharmaLt_mojoScore_3812395.png", "date": "2026-01-31 10:10:48", "description": "Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Are Piramal Pharma Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-piramal-pharma-ltd-latest-results-good-or-bad-3810126", "imagepath": "", "date": "2026-01-29 19:25:29", "description": "Piramal Pharma Ltd's latest financial results for Q3 FY26 reveal significant operational challenges. The company reported a consolidated net loss of ₹136.19 crores, marking a substantial decline compared to the previous year. Revenue for the quarter was ₹2,139.87 crores, reflecting a year-on-year decrease of 2.92%, although there was a sequential growth of 4.70% from the previous quarter. This indicates a concerning trend of weakening demand across its key business segments, which include contract development and manufacturing, complex hospital generics, and India consumer healthcare.\n\nThe operating margin (excluding other income) fell to 9.15%, down from 15.32% in the same quarter last year, highlighting severe margin compression. The profit before tax also turned negative, with a loss of ₹93.86 crores compared to a profit in the previous year. Employee costs have risen, reflecting ongoing investment in ta..." }, { "title": "Piramal Pharma Q3 FY26: Losses Deepen as Operational Challenges Mount", "link": "https://www.marketsmojo.com/news/result-analysis/piramal-pharma-q3-fy26-losses-deepen-as-operational-challenges-mount-3809542", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PiramalPharma_quaterlyResult_3809542.png", "date": "2026-01-29 10:35:55", "description": "Piramal Pharma Ltd. reported a consolidated net loss of ₹136.19 crores for Q3 FY26, marking a dramatic deterioration from the ₹3.68 crores profit posted in the same quarter last year. The loss widened 37.26% sequentially from Q2 FY26's ₹99.22 crores, highlighting deepening operational challenges at the ₹20,610 crores market capitalisation pharmaceutical company. The stock tumbled 3.18% to ₹159.15 following the results announcement, reflecting investor concerns over persistent profitability pressures despite modest revenue growth." } ], "total": 390, "sid": "1003728", "stock_news_url": "https://www.marketsmojo.com/news/piramal-pharma-1003728" }, "announcements": [ { "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA Inspection", "datetime": "14-Feb-2026", "details": "Please refer attachment", "source": "BSE" }, { "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revocation Of Closure Direction For CompanyS Dahej Site", "datetime": "14-Feb-2026", "details": "Please refer attachment", "source": "BSE" }, { "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015", "datetime": "11-Feb-2026", "details": "Please see enclosed disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Piramal Pharma Ltd has declared <strong>1%</strong> dividend, ex-date: 16 Jul 25", "dt": "2025-07-16", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Piramal Pharma Ltd has announced <strong>5:46</strong> rights issue, ex-date: 02 Aug 23", "dt": "2023-08-02", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

Jan 27: New 52-week low hit at Rs.150.15

Jan 28: Sharp surge in open interest signalling bearish market positioning

Jan 29: Further 52-week low recorded at Rs.148.3 amid volatile trading

Jan 30: Week closes at Rs.154.55, up 2.08% for the week

Read full news article

Piramal Pharma Ltd is Rated Strong Sell

2026-01-31 10:10:48

Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Piramal Pharma Ltd latest results good or bad?

2026-01-29 19:25:29

Piramal Pharma Ltd's latest financial results for Q3 FY26 reveal significant operational challenges. The company reported a consolidated net loss of ₹136.19 crores, marking a substantial decline compared to the previous year. Revenue for the quarter was ₹2,139.87 crores, reflecting a year-on-year decrease of 2.92%, although there was a sequential growth of 4.70% from the previous quarter. This indicates a concerning trend of weakening demand across its key business segments, which include contract development and manufacturing, complex hospital generics, and India consumer healthcare. The operating margin (excluding other income) fell to 9.15%, down from 15.32% in the same quarter last year, highlighting severe margin compression. The profit before tax also turned negative, with a loss of ₹93.86 crores compared to a profit in the previous year. Employee costs have risen, reflecting ongoing investment in ta...

Read full news article

Piramal Pharma Q3 FY26: Losses Deepen as Operational Challenges Mount

2026-01-29 10:35:55

Piramal Pharma Ltd. reported a consolidated net loss of ₹136.19 crores for Q3 FY26, marking a dramatic deterioration from the ₹3.68 crores profit posted in the same quarter last year. The loss widened 37.26% sequentially from Q2 FY26's ₹99.22 crores, highlighting deepening operational challenges at the ₹20,610 crores market capitalisation pharmaceutical company. The stock tumbled 3.18% to ₹159.15 following the results announcement, reflecting investor concerns over persistent profitability pressures despite modest revenue growth.

Read full news article